BriaCell Therapeutics Corp. (BCTXL)
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company, which engages in the development of novel immunotherapies to transform cancer care. It currently advancing its Bria-IMT™ targeted immunotherapy in combination with an immune check point inhibitor in a pivotal 1 Phase 3 study in metastatic breast cancer. The company was founded by Charles L. Wiseman and Isaac Benjamin Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
BriaCell Therapeutics Corp.
-2.44%$0.8000
CLOSED · Nov 17Prev close$0.8200-2.44%Close$0.8000
Mkt Cap$6.99M
EV-
Float8.72M
O/S8.73M
VOL79K sh
$ Vol$63K
RVOL4.64×
Inst Own-
SI0.1%
Net Cash/Sh-
Dilution
MCap$6.99MFloat8.72MO/S8.73M
Dilution